• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Health Group Reports Third Quarter 2023 Results

    11/7/23 6:45:00 AM ET
    $BHG
    Medical Specialities
    Health Care
    Get the next $BHG alert in real time by email
    • Q3'23 Revenue from Continuing Business of $269.4 million, up 39% year over year
    • Value-Based Consumers served of 355,000, an increase of 208.7% on a comparable basis from last year on strong growth in Care Delivery
    • Q3'23 Net Loss from Continuing Business of $479.3 million, including a $401.4 million non-cash Goodwill impairment charge; Positive Adjusted EBITDA of $1.2 million in Q3'23
    • Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability†

    Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported financial results for its Third Quarter ended September 30, 2023.

    "Bright Health's solid 2023 performance continued in the Third Quarter, with our second consecutive quarter of positive Adjusted EBITDA. Excluding a Goodwill impairment, our Care Delivery segment reported Operating Income profitability based on strong performance," said Mike Mikan, President and CEO of Bright Health. "We also continued to make good progress in the quarter on the wind-down of our ACA insurance business and the sale of our California Medicare Advantage business."

    Bright Health continues to work toward the approval of the sale of the Company's California Medicare Advantage business to Molina Healthcare, which was announced on June 30, 2023. The Company expects to close the transaction by the First Quarter of 2024.

    Key Metrics

     

    As of September 30,

     

    2023

     

    2022

    Consumer and Patient Metrics

     

     

     

    Value-Based Consumers served1

    355,000

     

    115,000

     

    1The value-based care consumers at September 30, 2022 have been recast for comparability to exclude approximately 409,000 consumers attributable to our Bright HealthCare- Commercial business that we exited beginning in 2023.

     

    Three Months Ended

     

    Nine Months Ended

    ($ in thousands)

    September 30,

     

    September 30,

     

    2023

     

    2022

     

    2023

     

    2022

    Financial Metrics

     

     

     

     

     

     

     

    Revenue

    $

    269,399

     

     

    $

    193,363

     

     

    $

    867,931

     

    ​

    $

    523,467

     

    Net Loss from Continuing Operations

    $

    (479,305

    )

     

    $

    (104,231

    )

     

    $

    (564,915

    )

    ​

    $

    (300,571

    )

    Adjusted EBITDA (non-GAAP)

    $

    1,205

     

     

    $

    (8,047

    )

     

    $

    1,876

     

     

    $

    (52,805

    )

    See the table at the end of this release for additional information and a reconciliation of the non-GAAP measures used in the table above.

    Financial Outlook

    For full year 2023, Bright Health is providing the following guidance and commentary:

    Bright Health is updating its 2023 financial outlook to reflect revised Revenue forecasts for the Care Solutions segment.

    • Bright Health's Enterprise Revenue is expected to be between $1.14 billion and $1.19 billion
    • On a segment basis, Care Solutions Revenue is expected to be between $890 million and $910 million, while Care Delivery Revenue is expected to be between $250 million and $275 million
    • Enterprise Adjusted Operating Cost Ratio is expected to be between 17.5% and 18.5%†
    • Bright Health expects to be Adjusted EBITDA profitable in 2023†

    † Reconciliations of projected Adjusted EBITDA and projected Adjusted Operating Cost Ratio to the most directly comparable GAAP financial measures are not provided because the Company is unable to provide such reconciliations without unreasonable effort. The inability to provide a reconciliation is due to the uncertainty and inherent difficulty predicting the occurrence, the financial impact and the periods in which the non-GAAP adjustments may be recognized. With respect to Adjusted EBITDA, these GAAP measures may include the impact of such items as interest expense, income tax expense, transaction costs, depreciation and amortization, share-based compensation expense, impairment of goodwill or intangible assets, restructuring costs, contract termination costs, changes in the fair value of contingent consideration, changes in the fair value of equity securities and derivatives, financial solvency of contractual counterparties; and the tax effect of all such items. Historically, the Company has excluded these items from non-GAAP financial measures. With respect to Adjusted Operating Cost Ratio, these GAAP measures may include the impact of such items as share-based compensation. The Company currently expects to continue to exclude these items in future disclosures of non-GAAP financial measures and may also exclude other items that may arise (collectively, "non-GAAP adjustments"). The decisions and events that typically lead to the recognition of non-GAAP adjustments, such as a decision to exit part of the business, are inherently unpredictable as to if or when they may occur. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

    Earnings Conference Call

    As previously announced, Bright Health Group will discuss the Company's results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today. Bright Health Group will host a live webcast of this conference call which can be accessed from the Investor Relations page of the company's website (investors.brighthealthgroup.com). Following the call, a webcast replay will be available on the same site. This earnings release and the Form 8-K filed November 7, 2023 can be accessed on the Investor Relations page of the Company's website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, U.S. Securities and Exchange Commission ("SEC") filings and public conference calls and webcasts.

    About Bright Health Group

    Bright Health Group is a technology enabled, value-driven healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in Florida, Texas and California, some of the largest markets in healthcare where 26% of the U.S. aging population call home. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.

    Forward-Looking Statements

    Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as "anticipate," "expect," "plan," "believe," "intend," "project," "forecast," "estimates," "projections," "outlook," "ensure," and other similar expressions. These forward-looking statements include any statements regarding our plans and expectations with respect to Bright Health Group, Inc. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: our ability to continue as a going concern; our ability to comply with the terms of our credit facilities, including financial covenants, both during and after any applicable waiver period, and/or obtain any additional waivers of any terms of our credit facilities to the extent required; our ability to sell our Medicare Advantage business in California on acceptable terms, including our ability to receive the proceeds thereof in a manner that would alleviate our current financial position; the failure to satisfy or obtain any waiver, if applicable, of any closing condition in our agreement to sell our Medicare Advantage business in California to Molina (the "Purchase Agreement"); our ability to comply with the terms of the Purchase Agreement; whether our credit facilities will satisfy our working capital needs pending the closing of our sale of our Medicare Advantage business in California; our ability to comply with the terms of the risk adjustment repayment agreements; our ability to obtain any additional short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently wind down our IFP businesses and MA businesses outside of California, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to our corporate restructuring and resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our businesses offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our Care Partner's abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to accurately estimate our medical expenses, effectively manage our costs and claims liabilities or appropriately price our products and charge premiums; our ability to obtain claims information timely and accurately; the impact of the ongoing COVID-19 pandemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage the growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions and integrate acquired businesses; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to the new risks associated with our expansion into ACO REACH; and the other factors set forth under the heading "Risk Factors" in the Company's reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.

    Bright Health Group, Inc. and Subsidiaries

    Consolidated Balance Sheets

    (in thousands, except share and per share data)

    (Unaudited)

     

     

    September 30,

    2023

     

    December 31,

    2022

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    113,430

     

     

    $

    217,006

     

    Short-term investments

     

    156

     

     

     

    869

     

    Accounts receivable, net of allowance of $8,932 and $6,098, respectively

     

    32,663

     

     

     

    19,576

     

    ACO REACH performance year receivable

     

    350,478

     

     

     

    99,181

     

    Current assets of discontinued operations

     

    1,368,694

     

     

     

    3,187,464

     

    Prepaids and other current assets

     

    46,542

     

     

     

    46,538

     

    Total current assets

     

    1,911,963

     

     

     

    3,570,634

     

    Other assets:

    ​

     

     

    Long-term investments

     

    344

     

     

     

    5,401

     

    Property, equipment and capitalized software, net

     

    17,517

     

     

     

    21,298

     

    Goodwill

     

    —

     

     

     

    401,385

     

    Intangible assets, net

     

    96,150

     

     

     

    104,952

     

    Long-term assets of discontinued operations

     

    —

     

     

     

    529,117

     

    Other non-current assets

     

    29,792

     

     

     

    32,265

     

    Total other assets

     

    143,803

     

     

     

    1,094,418

     

    Total assets

    $

    2,055,766

     

     

    $

    4,665,052

     

    Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders' Equity (Deficit)

     

     

    ​

    Current liabilities:

     

     

    ​

    Medical costs payable

    $

    169,778

     

     

    $

    116,021

     

    Accounts payable

     

    10,687

     

     

     

    18,714

     

    ACO REACH performance year obligation

     

    224,908

     

     

     

    —

     

    Short-term borrowings

     

    353,947

     

     

     

    303,947

     

    Current liabilities of discontinued operations

     

    974,502

     

     

     

    3,157,236

     

    Warrant liability

     

    9,874

     

     

     

    —

     

    Other current liabilities

     

    86,806

     

     

     

    97,241

     

    Total current liabilities

     

    1,830,502

     

     

     

    3,693,159

     

    Other liabilities

     

    30,655

     

     

     

    32,208

     

    Total liabilities

     

    1,861,157

     

     

     

    3,725,367

     

    Commitments and contingencies

    ​

     

    ​

    Redeemable noncontrolling interests

     

    327,263

     

     

     

    219,758

     

    Redeemable Series A preferred stock, $0.0001 par value; 750,000 shares authorized in 2023 and 2022; 750,000 shares issued and outstanding in 2023 and 2022

     

    747,481

     

     

     

    747,481

     

    Redeemable Series B preferred stock, $0.0001 par value; 175,000 shares authorized in 2023 and 2022; 175,000 shares issued and outstanding in 2023 and 2022

     

    172,936

     

     

     

    172,936

     

    Shareholders' equity (deficit):

     

     

     

    Common stock, $0.0001 par value; 3,000,000,000 shares authorized in 2023 and 2022; 7,981,802 and 7,878,394 shares issued and outstanding in 2023 and 2022*, respectively

     

    1

     

     

     

    1

     

    Additional paid-in capital

     

    3,037,946

     

     

     

    2,972,333

     

    Accumulated deficit

     

    (4,078,133

    )

     

     

    (3,156,395

    )

    Accumulated other comprehensive loss

     

    (885

    )

     

     

    (4,429

    )

    Treasury Stock, at cost, 31,526 shares at September 30, 2023, and December 31, 2022*, respectively

     

    (12,000

    )

     

     

    (12,000

    )

    Total shareholders' equity (deficit)

     

    (1,053,071

    )

     

     

    (200,490

    )

    Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders' equity (deficit)

    $

    2,055,766

     

     

    $

    4,665,052

     

     

    *Shares have been retroactively adjusted to reflect the reverse stock split effective May 22, 2023

    Bright Health Group, Inc. and Subsidiaries

    Consolidated Statements of Income (Loss)

    (in thousands, except share and per share data)

    (Unaudited)

     

    ​

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

    ​

    2023

     

    2022

     

    2023

     

    2022

    Revenue:

    ​

     

    ​

     

     

     

     

    Capitated revenue

    $

    60,371

     

     

    $

    33,006

     

     

    $

    159,683

     

     

    $

    79,295

     

    ACO REACH revenue

     

    200,044

     

     

     

    145,433

     

     

     

    676,845

     

     

     

    465,435

     

    Service revenue

     

    8,978

     

     

     

    10,076

     

     

     

    31,387

     

     

     

    31,038

     

    Investment income (loss)

     

    6

     

     

     

    4,848

     

     

     

    16

     

     

     

    (52,301

    )

    Total revenue

     

    269,399

     

     

     

    193,363

     

     

     

    867,931

     

     

     

    523,467

     

    Operating expenses:

     

     

     

     

     

     

     

    Medical costs

     

    226,438

     

     

     

    152,150

     

     

     

    731,718

     

     

     

    462,399

     

    Operating costs

     

    72,532

     

     

     

    85,566

     

     

     

    221,697

     

     

     

    261,351

     

    Goodwill impairment

     

    401,385

     

     

     

    —

     

     

     

    401,385

     

     

     

    —

     

    Intangible assets impairment

     

    —

     

     

     

    42,611

     

     

     

    —

     

     

     

    42,611

     

    Bad debt expense

     

    22,421

     

     

     

    11

     

     

     

    23,054

     

     

     

    11

     

    Restructuring charges

     

    5,281

     

     

     

    5

     

     

     

    6,867

     

     

     

    9,662

     

    Depreciation and amortization

     

    4,117

     

     

     

    8,947

     

     

     

    14,271

     

     

     

    25,283

     

    Total operating expenses

     

    732,174

     

     

     

    289,290

     

     

     

    1,398,992

     

     

     

    801,317

     

    Operating loss

     

    (462,775

    )

     

     

    (95,927

    )

     

     

    (531,061

    )

     

     

    (277,850

    )

    Interest expense

     

    10,041

     

     

     

    4,905

     

     

     

    26,998

     

     

     

    6,435

     

    Warrant expense

     

    9,874

     

     

     

    —

     

     

     

    9,874

     

     

     

    —

     

    Other income

     

    —

     

     

     

    (2

    )

     

     

    —

     

     

     

    —

     

    Loss from continuing operations before income taxes

     

    (482,690

    )

     

     

    (100,830

    )

     

     

    (567,933

    )

     

     

    (284,285

    )

    Income tax (benefit) expense

     

    (3,385

    )

     

     

    3,401

     

     

     

    (3,018

    )

     

     

    16,286

     

    Net loss from continuing operations

     

    (479,305

    )

     

     

    (104,231

    )

     

     

    (564,915

    )

     

     

    (300,571

    )

    Loss from discontinued operations, net of tax

     

    (67,843

    )

     

     

    (165,899

    )

     

     

    (240,321

    )

     

     

    (401,518

    )

    Net Loss

     

    (547,148

    )

     

     

    (270,130

    )

     

     

    (805,236

    )

     

     

    (702,089

    )

    Net earnings from continuing operations attributable to noncontrolling interests

     

    (86,747

    )

     

     

    (46,710

    )

     

     

    (116,502

    )

     

     

    (84,651

    )

    Series A preferred stock dividend accrued

     

    (10,178

    )

     

     

    (9,684

    )

     

     

    (29,834

    )

    ​

     

    (28,083

    )

    Series B preferred stock dividend accrued

     

    (2,284

    )

     

     

    —

     

     

     

    (6,695

    )

     

     

    —

     

    Net loss attributable to Bright Health Group, Inc. common shareholders

    $

    (646,357

    )

     

    $

    (326,524

    )

     

    $

    (958,267

    )

     

    $

    (814,823

    )

     

     

     

     

     

     

     

     

    Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders

     

     

     

     

     

     

     

    Continuing operations

    $

    (72.52

    )

     

    $

    (20.41

    )

     

    $

    (90.36

    )

     

    $

    (52.55

    )

    Discontinued operations

     

    (8.51

    )

     

     

    (21.07

    )

     

     

    (30.25

    )

     

     

    (51.05

    )

    Basic and diluted loss per share

     

    (81.03

    )

     

     

    (41.48

    )

     

     

    (120.61

    )

     

     

    (103.60

    )

     

     

     

     

     

     

     

     

    Basic and diluted weighted-average common shares outstanding*

     

    7,977

     

     

     

    7,871

     

     

     

    7,945

     

     

     

    7,865

     

     

    *Shares have been retroactively adjusted to reflect the reverse stock split effective May 22, 2023

    Bright Health Group, Inc. and Subsidiaries

    Consolidated Statements of Cash Flows

    (in thousands)

    (Unaudited)

     

    ​

    Nine Months Ended September 30,

    ​

    2023

     

    2022

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (805,236

    )

     

    $

    (702,089

    )

    Adjustments to reconcile net loss to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    20,149

     

     

     

    40,173

     

    Impairment of intangible assets

     

    —

     

     

     

    49,331

     

    Impairment of goodwill

     

    401,385

     

     

     

    74,165

     

    Share-based compensation

     

    65,611

     

     

     

    77,263

     

    Deferred income taxes

     

    (3,063

    )

     

     

    1,590

     

    Unrealized loss on equity securities

     

    —

     

     

     

    58,821

     

    Amortization of investments

     

    (17,946

    )

     

     

    3,236

     

    Warrant expense

     

    9,874

     

     

     

    —

     

    Other, net

     

    3,812

     

     

     

    6,377

     

    Changes in assets and liabilities, net of acquired assets and liabilities:

     

     

     

    Accounts receivable

     

    (27,438

    )

     

     

    10,934

     

    ACO REACH performance year receivable

     

    (251,297

    )

     

     

    (234,776

    )

    Other assets

     

    132,645

     

     

     

    (77,551

    )

    Medical cost payable

     

    (610,027

    )

     

     

    149,970

     

    Risk adjustment payable

     

    (1,541,536

    )

     

     

    377,789

     

    Accounts payable and other liabilities

     

    (124,295

    )

     

     

    (21,188

    )

    Unearned revenue

     

    127,135

     

     

     

    142,597

     

    ACO REACH performance year obligation

     

    224,908

     

     

     

    155,145

     

    Net cash (used in) provided by operating activities

     

    (2,395,319

    )

     

     

    111,787

     

    Cash flows from investing activities:

     

     

     

    Purchases of investments

     

    (830,176

    )

     

     

    (1,422,025

    )

    Proceeds from sales, paydown, and maturities of investments

     

    1,978,925

     

     

     

    980,763

     

    Purchases of property and equipment

     

    (2,626

    )

     

     

    (21,579

    )

    Business divestitures, net of cash disposed of

     

    (682

    )

     

     

    —

     

    Business acquisitions, net of cash acquired

     

    —

     

     

     

    (310

    )

    Net cash provided by (used in) investing activities

     

    1,145,441

     

     

     

    (463,151

    )

    Cash flows from financing activities:

     

     

     

    Net proceeds from short-term borrowings

     

    50,000

     

     

     

    148,947

     

    Proceeds from issuance of preferred stock

     

    —

     

     

     

    747,481

     

    Proceeds from issuance of common stock

     

    2

     

     

     

    1,314

     

    Distributions to noncontrolling interest holders

     

    (8,997

    )

     

     

    (2,032

    )

    Net cash (used in) provided by financing activities

     

    41,005

     

     

     

    895,710

     

    Net (decrease)/ increase in cash and cash equivalents

     

    (1,208,873

    )

     

     

    544,346

     

    Cash and cash equivalents – beginning of year

     

    1,932,290

     

     

     

    1,061,179

     

    Cash and cash equivalents – end of period

    $

    723,417

     

     

    $

    1,605,525

     

    Bright Health Group, Inc. and Subsidiaries

    Segment Information

    (in thousands)

    (Unaudited)

     

    Care Delivery

     

     

     

     

     

     

     

    ($ in thousands)

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

    Statement of income (loss) and operating data:

    2023

     

    2022

     

    2023

     

    2022

     

     

     

     

     

     

     

     

    Revenue:

     

     

     

     

     

     

     

    Capitated revenue

    $

    60,371

     

     

    $

    33,006

     

     

    $

    159,683

     

     

    $

    79,295

     

    Service revenue

     

    8,245

     

     

     

    10,050

     

     

     

    29,711

     

     

     

    30,960

     

    Total unaffiliated revenue

     

    68,616

     

     

     

    43,056

     

     

     

    189,394

     

     

     

    110,255

     

    Affiliated revenue

     

    (1,482

    )

     

     

    257,707

     

     

     

    6,487

     

     

     

    830,098

     

    Total segment revenue

     

    67,134

     

     

     

    300,763

     

     

     

    195,881

     

     

     

    940,353

     

    Operating expenses

     

     

     

     

     

     

     

    Medical Costs

     

    20,883

     

     

     

    264,013

     

     

     

    64,325

     

     

     

    850,011

     

    Operating Costs

     

    32,329

     

     

     

    30,388

     

     

     

    93,026

     

     

     

    93,984

     

    Goodwill impairment

     

    401,385

     

     

     

    —

     

     

     

    401,385

     

     

     

    —

     

    Intangible assets impairment

     

    —

     

     

     

    42,611

     

     

     

    —

     

     

     

    42,611

     

    Bad debt expense

     

    8

     

     

     

    4

     

     

     

    639

     

     

     

    4

     

    Restructuring charges

     

    130

     

     

     

    —

     

     

     

    130

     

     

     

    —

     

    Depreciation and amortization

     

    3,160

     

     

     

    6,374

     

     

     

    9,470

     

     

     

    19,119

     

    Total operating expenses

     

    457,895

     

     

     

    343,390

     

     

     

    568,975

     

     

     

    1,005,729

     

    Operating income (loss)

    $

    (390,761

    )

     

    $

    (42,627

    )

     

    $

    (373,094

    )

     

    $

    (65,376

    )

    Care Solutions

     

     

     

     

     

     

     

    ($ in thousands)

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

    Statement of income (loss) and operating data:

    2023

     

    2022

     

    2023

     

    2022

     

     

     

     

     

     

     

     

    Revenue:

     

     

     

     

     

     

     

    ACO REACH revenue

    $

    200,044

     

     

    $

    145,433

     

     

    $

    676,845

     

     

    $

    465,435

    Service revenue

     

    733

     

     

     

    26

     

     

     

    1,676

     

     

     

    78

    Total segment revenue

     

    200,777

     

     

     

    145,459

     

     

     

    678,521

     

     

     

    465,513

    Operating expenses

     

     

     

     

     

     

     

    Medical Costs

     

    204,017

     

     

     

    146,253

     

     

     

    673,891

     

     

     

    457,161

    Operating Costs

     

    3,702

     

     

     

    2,321

     

     

     

    10,083

     

     

     

    6,478

    Bad debt expense

     

    22,413

     

     

     

    —

     

     

     

    22,415

     

     

     

    —

    Total operating expenses

     

    230,132

     

     

     

    148,574

     

     

     

    706,389

     

     

     

    463,639

    Operating income

    $

    (29,355

    )

     

    $

    (3,115

    )

     

    $

    (27,868

    )

     

    $

    1,874

    Non-GAAP Financial Measures

    We use the non-GAAP financial measures Adjusted EBITDA, Adjusted Operating Cost Ratio, and Consumer Care Adjusted EBITDA (Consumer Care is defined as an aggregation of our Care Delivery and Care Solutions segments). We define Adjusted EBITDA as Net Loss excluding loss from discontinued operations, interest expense, income taxes, transaction costs, depreciation and amortization, share-based compensation expense, restructuring and contract termination costs, impairment of goodwill and intangible assets, changes in the fair value of contingent consideration, and changes in the fair value of equity securities and derivatives, and losses related to the bankruptcy of one of our ACO REACH partners. We define Adjusted Operating Cost Ratio as Operating Cost Ratio excluding share-based compensation expense. We define Consumer Care Adjusted EBITDA as Consumer Care Net Loss excluding depreciation and amortization, restructuring and contract termination costs, impairment of goodwill and intangible assets, losses related to the bankruptcy of one of our ACO REACH partners, and changes in fair value of contingent consideration. These non-GAAP measures have been presented in this quarterly Earnings Release or in the earnings conference call as supplemental measures of financial performance that are not required by or presented in accordance with GAAP because we believe they assist management and investors in comparing our operating performance across reporting periods on a consistent basis by excluding and including items that we do not believe are indicative of our core operating performance. Management believes these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses Adjusted EBITDA, Adjusted Operating Cost Ratio, and Consumer Care Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

    Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to Net Income (Loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a measure of free cash flow available for management's discretionary use as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentation of Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    Adjusted Operating Cost Ratio is not a recognized term under GAAP and should not be considered as an alternative to Operating Cost Ratio as a measure of financial performance or any other performance measure derived in accordance with GAAP. The presentation of Adjusted Operating Cost Ratio has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    Consumer Care Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to Consumer Care Net Loss as a measure of financial performance or any other performance measure derived in accordance with GAAP. The presentation of Consumer Care Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    The following table provides a reconciliation of net loss to Adjusted EBITDA for the periods presented:

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

    ($ in thousands)

    2023

     

    2022

     

    2023

     

    2022

    Net loss

    $

    (547,148

    )

     

    $

    (270,130

    )

     

    $

    (805,236

    )

     

    $

    (702,089

    )

    Loss from Discontinued Operations (a)

     

    67,843

     

     

     

    165,899

     

     

     

    240,321

     

     

     

    401,518

     

    EBITDA adjustments from continuing operations

     

     

     

     

     

     

     

    Interest expense

     

    10,041

     

     

     

    4,905

     

     

     

    26,998

     

     

     

    6,435

     

    Income tax (benefit) expense

     

    (3,385

    )

     

     

    3,401

     

     

     

    (3,018

    )

     

     

    16,286

     

    Transaction costs (b)

     

    8,941

     

     

     

    4

     

     

     

    18,889

     

     

     

    386

     

    Depreciation and amortization

     

    4,117

     

     

     

    8,947

     

     

     

    14,271

     

     

     

    25,283

     

    Share-based compensation expense (c)

     

    16,515

     

     

     

    24,123

     

     

     

    65,611

     

     

     

    77,263

     

    Restructuring and contract termination costs (d)

     

    5,281

     

     

     

    5

     

     

     

    6,867

     

     

     

    10,162

     

    Impairment of goodwill and intangible assets

     

    401,385

     

     

     

    42,611

     

     

     

    401,385

     

     

     

    42,611

     

    ACO REACH care partner bankruptcy (e)

     

    27,741

     

     

     

    —

     

     

     

    27,741

     

     

     

    —

     

    Change in fair value of warrant liability (f)

     

    9,874

     

     

     

    —

     

     

     

    9,874

     

     

     

    —

     

    Change in fair value of contingent consideration (g)

     

    —

     

     

     

    —

     

     

     

    (1,827

    )

     

     

    —

     

    Change in fair value of equity securities

     

    —

     

     

     

    12,188

     

     

     

    —

     

     

     

    69,340

     

    EBITDA adjustments from continuing operations

    $

    480,510

     

     

    $

    96,184

     

     

    $

    566,791

     

     

    $

    247,766

     

    Adjusted EBITDA

    $

    1,205

     

     

    $

    (8,047

    )

     

    $

    1,876

     

     

    $

    (52,805

    )

    (a)

    Beginning in the fourth quarter of 2022, Adjusted EBITDA excludes the impact of discontinued operations. The comparable period in 2022 has been recast to exclude these impacts. Represents losses associated with the Commercial business segment and MA Legacy operations that we exited at the end of 2022 and the California Medicare Advantage business classified as held for sale.

    (b)

    Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to financing initiatives. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business.

    (c)

    Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards.

    (d)

    Restructuring and contract termination costs represent severance costs as part of a workforce reduction, amounts paid for early termination of leases, and impairment of certain long-lived assets primarily relating to our decision to exit the Commercial business for the 2023 plan year.

    (e)

    Represents the costs expected to be incurred as a result of one of our ACO REACH care partners filing for bankruptcy; includes the full allowance established for the outstanding receivable and ongoing costs incurred to manage and provide service to members attributed to the care partner that would have otherwise been reimbursed prior to the care partner's bankruptcy.

    (f)

    Represents the non-cash change in the fair value of the warrant liability established for warrants included in our financing arrangements, which are remeasured at fair value each reporting period.

    (g)

    Represents the non-cash change in fair value of contingent consideration from business combinations, which is remeasured at fair value each reporting period.

    The following table provides a reconciliation of Adjusted Operating Cost Ratio for the periods presented:

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

    2023

     

    2022

     

    2023

     

    2022

    Operating Cost Ratio

    26.9%

     

    44.3%

     

    25.5%

     

    49.9%

    Impact of share-based compensation expense (a)

    (6.1)%

     

    (12.5)%

     

    (7.6)%

     

    (14.8)%

    Adjusted Operating Cost Ratio (b)

    20.8%

     

    31.8%

     

    18.0%

     

    35.2%

    (a)

    Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards.

    (b)

    The three months ended September 30, 2022 is lower by 0.8% and the nine months ended September 30, 2022 is higher by 3.2%, respectively, due to the impacts of income (loss) driven from unrealized gains and losses on equity securities and realized gains and losses on sales of investments.

    The following table provides a reconciliation of Care Delivery net loss to Care Delivery Adjusted EBITDA for the periods presented:

    Care Delivery

     

     

     

     

     

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

    ($ in thousands)

    2023

     

    2022

     

    2023

     

    2022

    Care Delivery Net Loss

    $

    (390,761

    )

     

    $

    (42,627

    )

     

    $

    (373,094

    )

     

    $

    (65,376

    )

    Interest expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Income tax (benefit) expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Transaction costs (a)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Depreciation and amortization

     

    3,160

     

     

     

    6,374

     

     

     

    9,470

     

     

     

    19,119

     

    Share-based compensation expense (b)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Restructuring and contract termination costs (c)

     

    130

     

     

     

    —

     

     

     

    130

     

     

     

    —

     

    Impairment of goodwill and intangible assets

     

    401,385

     

     

     

    42,611

     

     

     

    401,385

     

     

     

    42,611

     

    ACO REACH care partner bankruptcy (d)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Change in fair value of warrant liability (e)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Change in fair value of contingent consideration (f)

     

    —

     

     

     

    —

     

     

     

    (1,827

    )

     

     

    —

     

    Change in fair value of equity securities

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Care Delivery Adjusted EBITDA

    $

    13,914

     

     

    $

    6,358

     

     

    $

    36,064

     

     

    $

    (3,646

    )

    The following table provides a reconciliation of Care Solutions net loss to Care Solutions Adjusted EBITDA for the periods presented:

    Care Solutions

     

     

     

     

     

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

    ($ in thousands)

    2023

     

    2022

     

    2023

     

    2022

    Care Solutions Net loss

    $

    (29,355

    )

     

    $

    (3,115

    )

     

    $

    (27,868

    )

     

    $

    1,874

    Interest expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Income tax (benefit) expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Transaction costs (a)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Depreciation and amortization

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Share-based compensation expense (b)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Restructuring and contract termination costs (c)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Impairment of goodwill and intangible assets

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    ACO REACH care partner bankruptcy (d)

     

    27,741

     

     

     

    —

     

     

     

    27,741

     

     

     

    —

    Change in fair value of warrant liability (e)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Change in fair value of contingent consideration (f)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Change in fair value of equity securities

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

    Care Solutions Adjusted EBITDA

    $

    (1,614

    )

     

    $

    (3,115

    )

     

    $

    (127

    )

     

    $

    1,874

    The following table combines Care Delivery Adjusted EBITDA and Care Solutions Adjusted EBITDA, the aggregation of which we refer to as Consumer Care Adjusted EBITDA, for the periods presented:

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

    ($ in thousands)

    2023

     

    2022

     

    2023

     

    2022

    Care Delivery Adjusted EBITDA

    $

    13,914

     

     

    $

    6,358

     

     

    $

    36,064

     

     

    $

    (3,646

    )

    Care Solutions Adjusted EBITDA

     

    (1,614

    )

     

     

    (3,115

    )

     

     

    (127

    )

     

     

    1,874

     

    Consumer Care Adjusted EBITDA

    $

    12,300

     

     

    $

    3,243

     

     

    $

    35,937

     

     

    $

    (1,772

    )

    (a)

    Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to financing initiatives. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business.

    (b)

    Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards.

    (c)

    Restructuring and contract termination costs represent severance costs as part of a workforce reduction, amounts paid for early termination of leases, and impairment of certain long-lived assets primarily relating to our decision to exit the Commercial business for the 2023 plan year.

    (d)

    Represents the costs expected to be incurred as a result of one of our ACO REACH care partners filing for bankruptcy; includes the full allowance established for the outstanding receivable and ongoing costs incurred to manage and provide service to members attributed to the care partner that would have otherwise been reimbursed prior to the care partner's bankruptcy.

    (e)

    Represents the non-cash change in the fair value of the warrant liability established for warrants included in our financing arrangements, which are remeasured at fair value each reporting period.

    (f)

    Represents the non-cash change in fair value of contingent consideration from business combinations, which is remeasured at fair value each reporting period.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231107262580/en/

    Get the next $BHG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHG

    DatePrice TargetRatingAnalyst
    10/11/2022Neutral → Underweight
    JP Morgan
    3/29/2022Overweight → Neutral
    JP Morgan
    3/4/2022$9.00 → $3.00Outperform → Sector Perform
    RBC Capital
    3/3/2022$4.00 → $2.00Underweight
    Morgan Stanley
    3/3/2022$5.00 → $3.50Neutral
    Goldman Sachs
    3/3/2022$5.50 → $4.00Overweight
    Barclays
    3/3/2022$10.00 → $5.00Overweight
    Piper Sandler
    3/2/2022Buy → Underperform
    BofA Securities
    More analyst ratings

    $BHG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bright Health Group downgraded by JP Morgan

      JP Morgan downgraded Bright Health Group from Neutral to Underweight

      10/11/22 12:28:36 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group downgraded by JP Morgan

      JP Morgan downgraded Bright Health Group from Overweight to Neutral

      3/29/22 7:08:00 AM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Gr downgraded by RBC Capital with a new price target

      RBC Capital downgraded Bright Health Gr from Outperform to Sector Perform and set a new price target of $3.00 from $9.00 previously

      3/4/22 6:06:15 AM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Financials

    Live finance-specific insights

    See more
    • Bright Health Group Reports Third Quarter 2023 Results

      Q3'23 Revenue from Continuing Business of $269.4 million, up 39% year over year Value-Based Consumers served of 355,000, an increase of 208.7% on a comparable basis from last year on strong growth in Care Delivery Q3'23 Net Loss from Continuing Business of $479.3 million, including a $401.4 million non-cash Goodwill impairment charge; Positive Adjusted EBITDA of $1.2 million in Q3'23 Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability† Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported financial r

      11/7/23 6:45:00 AM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group to Host Third Quarter 2023 Earnings Conference Call on November 7, 2023

      Bright Health Group, Inc. ("Bright Health") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced it will report Third Quarter financial results before the financial markets open on Tuesday, November 7, 2023, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via Bright Health's Investor Relations page at investors.brighthe

      10/13/23 8:00:00 AM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Reports Second Quarter 2023 Results

      Q2'23 Revenue from Continuing Business of $298.0 million, up 100% year over year Value-Based Consumers served of 371,000, an increase of 214% on a comparable basis from last year on strong growth in Care Delivery Q2'23 Net Loss from Continuing Business of $31.7 million; Positive Adjusted EBITDA of $6.4 million in Q2'23, positive Operating Income in Care Delivery and Care Solutions segments Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability† Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported fi

      8/9/23 6:45:00 AM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Health Group Appoints Jay Matushak as Chief Financial Officer

      Cathy Smith to Step Down to Pursue New Opportunity, Effective May 12, 2023 Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today announced that it has appointed Jay Matushak as the Company's next Chief Financial Officer, effective May 12, 2023. Mr. Matushak will succeed Cathy Smith, who is stepping down to pursue another opportunity. Mr. Matushak, a seasoned finance and operational executive with deep expertise in the healthcare business, joined Bright Health in 2021. He currently serves as Senior Vice President of Finance and is responsible

      5/3/23 5:00:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Announces Retirement of General Counsel Keith Nelsen

      Jeff Craig, lead counsel for the Company's NeueHealth business, named General Counsel and Corporate Secretary Bright Health Group, Inc. ("Bright Health" or "The Company") (NYSE:BHG), the first technology-enabled, Fully Aligned system of care built for healthcare's consumer retail market, today announced that Keith Nelsen will retire as General Counsel and Corporate Secretary. Jeff Craig, lead counsel for the Company's NeueHealth business, will be promoted to the role of General Counsel and Corporate Secretary effective March 18, 2022. Nelsen will stay on as a senior advisor with the Company until June 30, 2022, to ensure a smooth transition. "Keith has been a key leader for many of our mi

      3/15/22 4:35:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Names Leading Healthcare Expert to Board

      Matthew Manders to Join as Independent Director Bright Health Group, Inc. ("Bright Health") (NYSE:BHG), the first technology-enabled, Fully Aligned system of care built for healthcare's consumer retail market, today announced that leading healthcare expert Matt Manders will join the company's Board as an independent director, effective March 1. Manders brings a wealth of diverse healthcare experience, focus on operational excellence, and expertise in consumer-driven healthcare. Most recently, he served as president of Cigna Corporation's Government and Solutions organization, part of a 30-plus-year career with the company. In this role, Manders led and managed Cigna's U.S. Government busi

      3/1/22 8:10:00 AM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bright Health Group Inc. (Amendment)

      SC 13G/A - NeueHealth, Inc. (0001671284) (Subject)

      2/14/24 5:04:52 PM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Bright Health Group Inc. (Amendment)

      SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)

      2/14/24 9:37:57 AM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Bright Health Group Inc. (Amendment)

      SC 13D/A - Bright Health Group Inc. (0001671284) (Subject)

      12/22/23 4:34:44 PM ET
      $BHG
      Medical Specialities
      Health Care

    $BHG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BHG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BHG
    SEC Filings

    See more
    • SEC Form 4 filed by Yang Rick

      4 - Bright Health Group Inc. (0001671284) (Issuer)

      12/21/23 5:05:33 PM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Walker Paul Edward

      4 - Bright Health Group Inc. (0001671284) (Issuer)

      12/21/23 5:04:41 PM ET
      $BHG
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Sandell Scott D

      4 - Bright Health Group Inc. (0001671284) (Issuer)

      12/21/23 5:02:52 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Adopts NeueHealth as Corporate Brand Name

      The Company will advance its value-driven, consumer-centric care model through its owned and affiliated clinics and provider enablement services Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG) today announced that it has adopted NeueHealth as its corporate brand name. This reflects the Company's ongoing focus on its NeueHealth business, which will continue driving long-term sustainable growth of its value-driven, consumer-centric care model, thereby increasing access to high-quality healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid. The Company's common stock will begin trading under the new ticker symbol "NEUE" on the New York Stock

      1/17/24 4:05:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Closes the Sale of its California Medicare Advantage Business to Molina Healthcare

      Completes final repayment on secured credit facility eliminating the Company's secured debt Further focuses on increasing access to value-driven healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid through its continuing business, NeueHealth Reaffirms expectation for Adjusted EBITDA profitability in 2024 Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced that it has successfully completed the sale of its California Medicare Advantage business, Brand New Day and Central Health Plan, to Molina Healthcare, Inc. ("Molina"). The sale closed, effective as of Januar

      1/2/24 4:30:00 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Strengthens Capital Position with Amendment to its Credit Facility, Impending Close of the Sale of its California Medicare Advantage Business

      Received all required regulatory approvals on the sale of the California Medicare Advantage business; the transaction is expected to close on or about January 1, 2024 Amended Company's secured credit facility to reduce the final repayment resulting in approximately $30 million in savings Meaningfully improves capital position to support continuing business, NeueHealth, a value-driven consumer care delivery and provider enablement business Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced that it entered into an amendment to its credit facility with J.P. Morgan that will reduce the final

      12/29/23 6:45:00 AM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Bright Health Group Inc. (0001671284) (Filer)

      1/24/24 5:09:44 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Bright Health Group Inc. (0001671284) (Filer)

      1/4/24 9:17:32 PM ET
      $BHG
      Medical Specialities
      Health Care
    • Bright Health Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Bright Health Group Inc. (0001671284) (Filer)

      1/2/24 4:32:58 PM ET
      $BHG
      Medical Specialities
      Health Care